CoChat

Interferon-Alpha Reduces Human Hippocampal Neurogenesis and Increases Apoptosis via Activation of Distinct STAT1-Dependent Mechanisms

Open access
Borsini, Alessandra, Cattaneo, Annamaria, Malpighi, Chiara, Thuret, Sandrine, Harrison, Neil A, MRC ImmunoPsychiatry Consortium, Zunszain, Patricia A, Pariante, Carmine M · 2018 · International Journal of Neuropsychopharmacology

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

Background: In humans, interferon-α treatment for chronic viral hepatitis is a well-recognized clinical model for inflammation-induced depression, but the molecular mechanisms underlying these effects are not clear. Following peripheral administration in rodents, interferon-α induces signal transducer and activator of transcription-1 (STAT1) within the hippocampus and disrupts hippocampal neurogenesis. Methods: We used the human hippocampal progenitor cell line HPC0A07/03C to evaluate the effects of 2 concentrations of interferon-α, similar to those observed in human serum during its therapeutic use (500 pg/mL and 5000 pg/mL), on neurogenesis and apoptosis. Results: Both concentrations of interferon-α decreased hippocampal neurogenesis, with the high concentration also increasing apoptosis. Moreover, interferon-α increased the expression of interferon-stimulated gene 15 (ISG15), ubiquitin-specific peptidase 18 (USP18), and interleukin-6 (IL-6) via activation of STAT1. Like interferon-α, co-treatment with a combination of ISG15, USP18, and IL-6 was able to reduce neurogenesis and enhance apoptosis via further downstream activation of STAT1. Further experiments showed that ISG15 and USP18 mediated the interferon-α-induced reduction in neurogenesis (potentially through upregulation of the ISGylation-related proteins UBA7, UBE2L6, and HERC5), while IL-6 mediated the interferon-α-induced increase in apoptosis (potentially through downregulation of aquaporin 4). Using transcriptomic analyses, we showed that interferon-α regulated pathways involved in oxidative stress and immune response (e.g., Nuclear Factor (erythroid-derived 2)-like 2 [Nrf2] and interferon regulatory factor [IRF] signaling pathway), neuronal formation (e.g., CAMP response element-binding protein [CREB] signaling), and cell death regulation (e.g., tumor protein(p)53 signaling). Conclusions: We identify novel molecular mechanisms mediating the effects of interferon-α on the human hippocampus potentially involved in inflammation-induced neuropsychiatric symptoms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ijnp/pyx083

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Interferon (IFN)-α reduces differentiation, increases apoptosis, and upregulates signal transducer and activator of transcription-1 (STAT1), interferon-stimulated gene 15 (ISG15), and ubiquitin-specific peptidase 18 (USP18) gene expression. IFN-α (500 and 5000 pg/mL) decreased doublecortin (DCX)+ (a) and microtubule-associated protein 2 (MAP2)+ cells (b). IFN-α 5000 pg/mL increased both caspase 3 (CC3)+ cells (c) and CC3+/MAP2+ cells (d). IFN-α (500 and 5000 pg/mL) increased STAT1 (e), ISG15 (f), and USP18 (g) gene expression. Three independent experiments were conducted on independent cultures (n=3). Data are shown as mean±SEM. 1-way ANOVA, Newman–Keuls’ posthoc test *P<.05, **P<.01, ***P<.001, ****P<.0001, compared with vehicle treatment or as indicated.
Figure 1. Interferon (IFN)-α reduces differentiation, increases apoptosis, and upregulates signal transducer and activator of transcription-1 (STAT1), interferon-stimulated gene 15 (ISG15), and ubiquitin-specific peptidase 18 (USP18) gene expression. IFN-α (500 and 5000 pg/mL) decreased doublecortin (DCX)+ (a) and microtubule-associated protein 2 (MAP2)+ cells (b). IFN-α 5000 pg/mL increased both caspase 3 (CC3)+ cells (c) and CC3+/MAP2+ cells (d). IFN-α (500 and 5000 pg/mL) increased STAT1 (e), ISG15 (f), and USP18 (g) gene expression. Three independent experiments were conducted on independent cultures (n=3). Data are shown as mean±SEM. 1-way ANOVA, Newman–Keuls’ posthoc test *P<.05, **P<.01, ***P<.001, ****P<.0001, compared with vehicle treatment or as indicated.CC BY · PubMed Central
Figure 2. Cotreatment with interferon-stimulated gene 15 (ISG15), ubiquitin-specific peptidase 18 (USP18), and interleukin (IL)-6 mimics the effect of interferon (IFN)-α on neurogenesis and apoptosis. ISG15 and all proteins reduced doublecortin (DCX)+ cells (a). ISG15, USP18, and all proteins reduced microtubule-associated protein 2 (MAP2)+ cells (b). USP18 also decreased caspase 3 (CC3)+ cells, whereas IL-6 and all proteins significantly increased both CC3+ and CC3/MAP2+ cells (c-d). Three independent experiments were conducted on independent cultures (n=3). Data are shown as mean±SEM. 1-way ANOVA, Newman–Keuls’ posthoc test *P<.05, **P<.01, ***P<.001, compared with vehicle treatment or as indicated.
Figure 2. Cotreatment with interferon-stimulated gene 15 (ISG15), ubiquitin-specific peptidase 18 (USP18), and interleukin (IL)-6 mimics the effect of interferon (IFN)-α on neurogenesis and apoptosis. ISG15 and all proteins reduced doublecortin (DCX)+ cells (a). ISG15, USP18, and all proteins reduced microtubule-associated protein 2 (MAP2)+ cells (b). USP18 also decreased caspase 3 (CC3)+ cells, whereas IL-6 and all proteins significantly increased both CC3+ and CC3/MAP2+ cells (c-d). Three independent experiments were conducted on independent cultures (n=3). Data are shown as mean±SEM. 1-way ANOVA, Newman–Keuls’ posthoc test *P<.05, **P<.01, ***P<.001, compared with vehicle treatment or as indicated.CC BY · PubMed Central
Figure 3. Interleukin (IL)-6A prevents the effects of interferon (IFN)-α on apoptosis. Treatment with IL-6A prevented the increase in caspase 3 (CC3)+ and CC3/microtubule-associated protein 2 (MAP2)+ cells detected upon IFN-α 5000 pg/mL (c-d). Three independent experiments were conducted on independent cultures (n=3). Data are shown as mean±SEM. 1-way ANOVA, Newman–Keuls’ posthoc test *P<.05, **P<.01, ****P<.0001, compared with vehicle treatment or as indicated.
Figure 3. Interleukin (IL)-6A prevents the effects of interferon (IFN)-α on apoptosis. Treatment with IL-6A prevented the increase in caspase 3 (CC3)+ and CC3/microtubule-associated protein 2 (MAP2)+ cells detected upon IFN-α 5000 pg/mL (c-d). Three independent experiments were conducted on independent cultures (n=3). Data are shown as mean±SEM. 1-way ANOVA, Newman–Keuls’ posthoc test *P<.05, **P<.01, ****P<.0001, compared with vehicle treatment or as indicated.CC BY · PubMed Central
Figure 4. Treatment with a signal transducer and activator of transcription-1 (STAT1) inhibitor reverts the effects of interferon (IFN)-α on neurogenesis and apoptosis by preventing the upregulation of interferon-stimulated gene 15 (ISG15), ubiquitin-specific peptidase 18 (USP18), and interleukin (IL)-6. Fludarabine prevented the decrease in doublecortin (DCX)+ and microtubule-associated protein 2 (MAP2)+ cells caused by IFN-α (500 and 5000 pg/mL) (a-b), as well as the decrease in caspase 3 (CC3)+ and CC3+/MAP2+ cells detected upon IFN-α 5000 pg/mL (c-d). Fludarabine prevented the increase in ISG15 (e) and USP18 (f) genes and IL-6 protein expression (g) observed upon IFN-α (500 and 5000 pg/mL). Three independent experiments were conducted on independent cultures (n=3). Data are shown as mean±SEM. 1-way ANOVA, Newman–Keuls’ posthoc test **P<.01, ***P<.001, ****P<.0001, compared with vehicle treatment or as indicated.
Figure 4. Treatment with a signal transducer and activator of transcription-1 (STAT1) inhibitor reverts the effects of interferon (IFN)-α on neurogenesis and apoptosis by preventing the upregulation of interferon-stimulated gene 15 (ISG15), ubiquitin-specific peptidase 18 (USP18), and interleukin (IL)-6. Fludarabine prevented the decrease in doublecortin (DCX)+ and microtubule-associated protein 2 (MAP2)+ cells caused by IFN-α (500 and 5000 pg/mL) (a-b), as well as the decrease in caspase 3 (CC3)+ and CC3+/MAP2+ cells detected upon IFN-α 5000 pg/mL (c-d). Fludarabine prevented the increase in ISG15 (e) and USP18 (f) genes and IL-6 protein expression (g) observed upon IFN-α (500 and 5000 pg/mL). Three independent experiments were conducted on independent cultures (n=3). Data are shown as mean±SEM. 1-way ANOVA, Newman–Keuls’ posthoc test **P<.01, ***P<.001, ****P<.0001, compared with vehicle treatment or as indicated.CC BY · PubMed Central
Figure 5. Treatment with a signal transducer and activator of transcription-1 (STAT1) inhibitor prevents the effect of interferon-stimulated gene 15 (ISG15) on neurogenesis and of interleukin (IL)-6 on apoptosis. Fludarabine prevented the decrease in microtubule-associated protein 2 (MAP2)+ cells caused by ISG15 and all proteins (b), as well as the increase in caspase 3 (CC3)+ and CC3+/MAP2+ cells detected upon treatment with IL-6 (c) and all proteins (d). Three independent experiments were conducted on independent cultures (n=3). Data are shown as mean±SEM. One-way ANOVA, Newman–Keuls’ posthoc test *P<.05, **P<.01, ****P<.0001, compared with vehicle treatment or as indicated.
Figure 5. Treatment with a signal transducer and activator of transcription-1 (STAT1) inhibitor prevents the effect of interferon-stimulated gene 15 (ISG15) on neurogenesis and of interleukin (IL)-6 on apoptosis. Fludarabine prevented the decrease in microtubule-associated protein 2 (MAP2)+ cells caused by ISG15 and all proteins (b), as well as the increase in caspase 3 (CC3)+ and CC3+/MAP2+ cells detected upon treatment with IL-6 (c) and all proteins (d). Three independent experiments were conducted on independent cultures (n=3). Data are shown as mean±SEM. One-way ANOVA, Newman–Keuls’ posthoc test *P<.05, **P<.01, ****P<.0001, compared with vehicle treatment or as indicated.CC BY · PubMed Central
Figure 6. Treatment with interferon (IFN)-α, interferon-stimulated gene 15 (ISG15), and all proteins increase UBA7, UBE2L6, and HERC5 gene expression via activation of signal transducer and activator of transcription-1 (STAT1) protein. IFN-α (500 and 5000 pg/mL) increased UBA7 (a), UBE2L6 (b), and HERC5 (c) gene expression, whereas cotreatment with fludarabine prevented such upregulation (a-c). ISG15 and all proteins induced UBA7 (d), UBE2L6 (e), and HERC5 (f). Cotreatment with either ISG15 or all proteins and fludarabine prevented such increase (d-f). Three independent experiments were conducted on independent cultures (n=3). Data are shown as mean±SEM. One-way ANOVA, Newman–Keuls’ posthoc test **P<.01, ***P<.001, ****P<.0001, compared with vehicle treatment or as indicated.
Figure 6. Treatment with interferon (IFN)-α, interferon-stimulated gene 15 (ISG15), and all proteins increase UBA7, UBE2L6, and HERC5 gene expression via activation of signal transducer and activator of transcription-1 (STAT1) protein. IFN-α (500 and 5000 pg/mL) increased UBA7 (a), UBE2L6 (b), and HERC5 (c) gene expression, whereas cotreatment with fludarabine prevented such upregulation (a-c). ISG15 and all proteins induced UBA7 (d), UBE2L6 (e), and HERC5 (f). Cotreatment with either ISG15 or all proteins and fludarabine prevented such increase (d-f). Three independent experiments were conducted on independent cultures (n=3). Data are shown as mean±SEM. One-way ANOVA, Newman–Keuls’ posthoc test **P<.01, ***P<.001, ****P<.0001, compared with vehicle treatment or as indicated.CC BY · PubMed Central
Figure 7. Treatment with interferon (IFN)-α, interleukin (IL)-6, and all proteins decrease AQP4 gene expression via activation of signal transducer and activator of transcription-1 (STAT1) protein. IFN-α 5000 pg/mL downregulated AQP4 gene expression, whereas cotreatment with IFN-α 5000 pg/mL and fludarabine prevented such downregulation (a). IL-6A blocked the reduction in AQP4 seen upon IFN-α 5000 pg/mL (b). Treatment with IL-6 and all proteins decreased AQP4 gene expression, whereas cotreatment of IL-6 or all proteins with fludarabine prevented the reduction in AQP4 gene expression (c). Three independent experiments were conducted on independent cultures (n=3). Data are shown as mean±SEM. 1-way ANOVA, Newman–Keuls’ posthoc test *P<.05, ***P<.001, compared with vehicle treatment or as indicated.
Figure 7. Treatment with interferon (IFN)-α, interleukin (IL)-6, and all proteins decrease AQP4 gene expression via activation of signal transducer and activator of transcription-1 (STAT1) protein. IFN-α 5000 pg/mL downregulated AQP4 gene expression, whereas cotreatment with IFN-α 5000 pg/mL and fludarabine prevented such downregulation (a). IL-6A blocked the reduction in AQP4 seen upon IFN-α 5000 pg/mL (b). Treatment with IL-6 and all proteins decreased AQP4 gene expression, whereas cotreatment of IL-6 or all proteins with fludarabine prevented the reduction in AQP4 gene expression (c). Three independent experiments were conducted on independent cultures (n=3). Data are shown as mean±SEM. 1-way ANOVA, Newman–Keuls’ posthoc test *P<.05, ***P<.001, compared with vehicle treatment or as indicated.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Cited by

See all 118

Metadata

Authors
Borsini, A., Cattaneo, A., Malpighi, C., Thuret, S., Harrison, N. A., MRC ImmunoPsychiatry Consortium, Zunszain, P. A., & Pariante, C. M.
Affiliations
  • King's College London (GB)
  • Brighton and Sussex Medical School (GB)
Corresponding author
Borsini, Alessandra
Venue
International Journal of Neuropsychopharmacology
Published
2017-10-10
Volume
21
Issue
2
Pages
187-200
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2763852601
Cited by
113
References
57
Citations by year
2026: 5 · 2025: 9 · 2024: 14 · 2023: 14 · 2022: 15 · 2021: 20 · 2020: 18 · 2019: 12 · 2018: 6
FWCI
4.17
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (publishedVersion, cc-by)
  • ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
  • Sussex Research Online (University of Sussex) (submittedVersion, cc-by)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Institute for Health Research
  • Department of Health
  • Alzheimer’s Society
Topics
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
Keywords
interferon-alpha, hippocampal neurogenesis, apoptosis, STAT1 signaling, ISG15, USP18, interleukin-6, ISGylation, aquaporin-4, Nrf2 signaling, CREB signaling, TP53 signaling, chronic viral hepatitis, hippocampal progenitor cells, neuropsychiatric symptoms
MeSH terms
Cell Line, Hippocampus, Humans, Inflammation, Stem Cells, Interferon-alpha, Apoptosis, STAT1 Transcription Factor, Neurogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interferon-Alpha Reduces Human Hippocampal Neurogenesis and Increases Apoptosis via Activation of Distinct STAT1-Dependent Mechanisms. https://app.cochat.ai/papers/10.1093/ijnp/pyx083
The paper
Borsini, A., Cattaneo, A., Malpighi, C., Thuret, S., Harrison, N. A., MRC ImmunoPsychiatry Consortium, Zunszain, P. A., & Pariante, C. M. (2018). Interferon-Alpha Reduces Human Hippocampal Neurogenesis and Increases Apoptosis via Activation of Distinct STAT1-Dependent Mechanisms. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyx083

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.